MOTS-C 30mg Review

MOTS-c occupies a genuinely unusual position in the peptide research landscape. Unlike most research peptides, which are either synthetic analogues of endogenous hormones or entirely exogenous sequences, MOTS-c is a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of the human mitochondrial genome. That makes it a mitochondrial-derived peptide (MDP), a class of signaling molecules only formally described in the peer-reviewed literature after 2013. The peptide has since attracted substantial interest from researchers studying insulin sensitivity, exercise physiology, metabolic homeostasis, and aging biology.

The 30 mg vial format reviewed here, supplied by Apollo Peptide Sciences, is the largest single-vial format widely available in the research market. That sizing is appropriate for extended longitudinal studies in rodent models, where per-animal doses in the literature range from 5 mg/kg to 15 mg/kg depending on endpoint, and multiple cohort arms are typically required for statistical power. This review systematically covers the compound's biochemistry, the published preclinical and early translational evidence, what a compliant certificate of analysis (CoA) should contain, and how the 30 mg format compares with the more common 5 mg and 10 mg vials offered by competing vendors.

Editor's Verdict

MOTS-c stands out among longevity-category research peptides because its endogenous origin is clearly defined at the molecular level. The 2015 Cell Metabolism paper by Lee et al. established both the sequence and the mitochondrial genomic locus from which it is translated, giving researchers a firm biological foundation that many purported "longevity peptides" lack. ^[1] Subsequent work from multiple independent groups has replicated the core finding that exogenous MOTS-c administration improves insulin sensitivity and reduces diet-induced obesity in murine models, ^[2] while more recent studies have extended the investigation to skeletal muscle, the brain, and immune compartments.

The Apollo Peptide Sciences 30 mg vial offers a practical advantage for research groups running multi-arm rodent studies: a single vial covers a complete study at literature-reported doses without reconstitution across multiple vials, reducing preparation variability. The price per milligram works out to approximately $5.00/mg, which is competitive with the major vendors in the research peptide market for this compound at this purity tier (typically reported as ≥98% by HPLC). Researchers should confirm this independently via the supplied CoA and, ideally, third-party mass spectrometry, as described in the purity section below.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Mitochondrial Genomic Origin

MOTS-c belongs to a newly characterized class of signaling peptides collectively termed mitochondrial-derived peptides (MDPs). The defining feature of MDPs is that they are encoded by short open reading frames (sORFs) within mitochondrial DNA (mtDNA) rather than nuclear DNA. This is a conceptually important distinction: canonical dogma held that mammalian mtDNA encodes only 13 protein-coding sequences (all subunits of the oxidative phosphorylation complexes), 22 transfer RNAs, and two ribosomal RNAs. The identification of functional peptides arising from sORFs embedded within rRNA genes broke that dogma. ^[1]

The MOTS-c reading frame sits within the 12S ribosomal RNA gene, which is located in the mitochondrial genome between base positions 648 and 1601 (human mtDNA reference sequence NC_012920). The sORF encoding MOTS-c spans 51 nucleotides and produces a 16-residue mature peptide. Lee et al. confirmed via ribosomal profiling and polysome gradient fractionation that the sORF is actively translated in human and murine cells, not merely present as a theoretical open reading frame. ^[1] The translated peptide is then exported from the mitochondria and can traffic to the nucleus, cytoplasm, and extracellular space, making it a genuinely intercellular signaling molecule.

The broader MDP family currently includes humanin (21 amino acids, encoded in the 16S rRNA gene), SHLP1-6 (small humanin-like peptides, also from the 16S rRNA region), and MOTS-c. Each family member has distinct tissue distributions, receptor interactions, and physiological roles. MOTS-c is the only MDP to date shown to translocate to the nucleus under metabolic stress, suggesting a role in direct transcriptional regulation. ^[3]

Sequence, Structure, and Physicochemical Properties

The canonical 16-amino-acid sequence MRWQEMGYIFYPRKLR encodes a peptide with a calculated molecular weight of approximately 2,174.77 Da and a net positive charge at physiological pH, driven by three basic residues (two arginines, one lysine) and the free N-terminal amine. The peptide contains one tryptophan and one tyrosine, which are UV-active, making 280 nm absorbance a useful purity indicator in HPLC analysis. It also contains a single methionine at the N-terminus; researchers handling reconstituted stocks should be aware that methionine is susceptible to oxidation, which can produce the sulfoxide form and reduce bioactivity. ^[4]

No high-resolution crystal or NMR structure of MOTS-c has been published as of early 2026. Circular dichroism data from Lee et al. (2015) suggest the peptide adopts predominantly random coil conformation in aqueous solution, which is consistent with its relatively small size and high polar residue content. Molecular dynamics simulations from one computational study proposed that MOTS-c may adopt a transient amphipathic helical structure in membrane-proximate environments, which could relate to its apparent cell-membrane-permeating capacity, but this remains a hypothesis rather than confirmed structural data. ^[5]

Synthesis and Purity Considerations

Research-grade MOTS-c is produced by solid-phase peptide synthesis (SPPS) using Fmoc chemistry, which is standard for peptides of this length. The 16-residue length is manageable for SPPS, but the presence of two arginines (positions 1 and 16 in some numbering conventions), which are prone to incomplete deprotection of Pbf groups, means that synthesis quality control is particularly important. Vendors should provide both HPLC chromatograms (typically reverse-phase C18, acetonitrile/water/TFA gradient) showing ≥98% peak area purity, and mass spectrometry confirmation showing the expected molecular ion. Electrospray ionization (ESI-MS) should show the [M+2H]²⁺ ion at approximately m/z 1088 and the [M+3H]³⁺ ion at approximately m/z 726. ^[1]

Mechanism of Action

AMPK Activation: The Core Pathway

The primary described mechanism by which MOTS-c exerts its metabolic effects is through activation of AMP-activated protein kinase (AMPK), the master energy-sensing kinase of eukaryotic cells. AMPK is activated when the cellular AMP:ATP ratio rises (indicating energy deficit) and phosphorylates hundreds of downstream targets to shift cells from anabolic to catabolic metabolism. What makes MOTS-c's mechanism distinctive is that it activates AMPK through an AICAR-like intermediate rather than through the canonical upstream kinase LKB1 or through direct AMP binding to the AMPK gamma subunit. ^[1]

Specifically, Lee et al. demonstrated that MOTS-c inhibits the folate cycle and de novo purine biosynthesis pathway in an intracellular fashion, leading to accumulation of the AMPK-activating metabolite AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). ^[1] AICAR is itself a pharmacological AMPK activator widely used in research (sold as AICA ribonucleotide), but the metabolic re-routing through folate pathway inhibition by MOTS-c represents a distinct, indirect mechanism. Knock-down of MOTS-c in cell culture using siRNA targeting the mtDNA-derived transcript reduces AMPK phosphorylation and blunts the metabolic effects, confirming pathway specificity. ^[2]

Downstream of AMPK activation, MOTS-c research has documented effects on: glucose transporter 4 (GLUT4) translocation to the plasma membrane (increasing skeletal muscle glucose uptake), fatty acid oxidation (via phosphorylation of acetyl-CoA carboxylase, ACC), and inhibition of hepatic gluconeogenesis (via CRTC2 phosphorylation). These are the same downstream effects sought by metformin and other biguanide drugs via AMPK, which is why MOTS-c has attracted interest as a potentially more targeted and less systemically disruptive research comparator. ^[6]

Nuclear Translocation and Transcriptional Effects

A mechanistically important 2019 study by Kim et al. published in Cell Metabolism demonstrated that under mitochondrial stress conditions, a portion of the intracellular MOTS-c pool translocates from the cytoplasm to the nucleus. ^[3] Once nuclear, MOTS-c binds directly to nuclear DNA at AT-rich sequences and modulates transcription of stress-response genes, particularly those involved in the integrated stress response (ISR) and mitohormesis. This is a remarkable finding for a 16-residue peptide, because it positions MOTS-c not merely as a kinase-pathway signal but as a potential direct transcriptional regulator.

The nuclear translocation of MOTS-c was shown to require the presence of the basic residues at the C-terminus (the KLR tripeptide), which appear to function as a nuclear localization signal. Truncation mutants lacking these residues failed to translocate and showed attenuated transcriptional effects without losing the ability to activate AMPK via the folate-AICAR pathway. ^[3] This suggests the peptide operates through two mechanistically separable pathways: the metabolic AMPK arm and the stress-responsive transcriptional arm. Researchers designing mechanistic studies should consider which arm they are targeting when selecting doses and endpoints.

Skeletal Muscle and Exercise Biology

A distinct line of MOTS-c research has focused on skeletal muscle. Reynolds et al. (2021), publishing in Nature Aging, demonstrated that circulating MOTS-c levels decline with age in both mice and humans and that exogenous MOTS-c administration to aged mice enhanced exercise capacity, improved muscle fiber type composition, and extended healthspan markers. ^[7] The proposed mechanism in skeletal muscle involves AMPK-driven mitochondrial biogenesis (via PGC-1alpha upregulation), enhanced fatty acid oxidation, and reduced ceramide accumulation, all of which have relevance to the age-associated decline in muscle oxidative capacity (sarcopenia).

The exercise-biology link has led some research groups to investigate MOTS-c as a potential "exercise mimetic", a compound that partially recapitulates the cellular adaptations of physical exercise at the molecular level. This framing carries important caveats: no clinical trial data in humans on exercise mimicry exists as of 2026, and the rodent exercise endpoints (treadmill run time, grip strength, VO2 max equivalents) have well-documented translation difficulties to human performance biology. The mechanistic plausibility is genuine; the translational confidence is not yet established.

Anti-Inflammatory and Immune-Modulatory Effects

More recent work has identified MOTS-c as a modulator of innate immune signaling. Lee et al. (2021) showed that MOTS-c suppresses LPS-induced inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) in macrophage cell cultures and attenuates systemic inflammation in an endotoxemia mouse model. ^[8] The proposed mechanism involves suppression of NF-kB pathway activation, possibly through AMPK-mediated phosphorylation of IKK (IkB kinase), which reduces nuclear translocation of NF-kB p65. This anti-inflammatory arm of MOTS-c biology has attracted interest from researchers studying sepsis, metabolic inflammation, and potentially neuroinflammation.

Tissue Distribution and Expression Patterns

Endogenous MOTS-c is expressed in proportion to mitochondrial content across tissues. Tissues with high mitochondrial density (skeletal muscle, cardiac muscle, liver, brain) express higher levels. Serum MOTS-c is detectable in healthy adults at concentrations in the low nanomolar range (approximately 0.1-0.5 nM based on ELISA data from multiple studies), and circulating levels respond acutely to exercise, declining transiently during high-intensity activity and recovering in the post-exercise window. ^[7] Serum levels decline significantly with aging; in the Reynolds et al. cohort, 75-year-old subjects showed serum MOTS-c approximately 35-40% lower than 25-year-old controls. ^[7]

What the Research Says

Study 1: Lee et al. (2015), Cell Metabolism - Discovery and Metabolic Effects

The foundational MOTS-c paper, published in Cell Metabolism in 2015 (PMID 25738459), established the existence, sequence, mitochondrial genomic locus, and primary metabolic function of MOTS-c. ^[1] The study design had multiple tiers: molecular confirmation of the sORF translation by ribosomal profiling, in-vitro mechanistic work in HeLa and primary human adipocytes, and in-vivo studies in C57BL/6 mice fed a high-fat diet (HFD). The mouse studies used intraperitoneal (IP) injection at 15 mg/kg daily, which is the animal-equivalent literature dose most frequently referenced in subsequent work.

The in-vivo HFD results are worth examining in detail. Mice receiving 15 mg/kg/day MOTS-c for four weeks gained significantly less body weight than vehicle controls (mean difference approximately 4.2g by week 4), had improved glucose tolerance by oral glucose tolerance test (oGTT AUC reduced by ~30%), and showed improved insulin sensitivity by insulin tolerance test (ITT). Liver mass and hepatic lipid content were also reduced in MOTS-c-treated animals. The study authors proposed MOTS-c as a potential therapeutic target for metabolic syndrome, but were careful to note that the doses used were supraphysiological relative to endogenous circulating levels and that the pharmacological mechanism (folate cycle disruption) required further characterization at lower doses. A critical limitation acknowledged was the reliance on IP delivery, which bypasses the first-pass hepatic considerations relevant to potential future translational work. ^[1]

Study 2: Zempo et al. (2021), International Journal of Molecular Sciences - Exercise and Aging

Zempo et al. published an important translational study in 2021 examining MOTS-c serum levels across the human age spectrum and in relation to physical activity status. ^[9] The cohort included 120 Japanese adults across four age groups (20-35, 40-55, 60-70, and 71-85 years) and stratified by physical activity level (sedentary vs. regularly active). The primary finding was a progressive age-related decline in serum MOTS-c, consistent with earlier rodent data, with the oldest sedentary group showing levels approximately 45% below the youngest group. Regularly active elderly subjects maintained MOTS-c levels approximately 20% higher than sedentary age-matched peers, suggesting that habitual exercise partially preserves MOTS-c output. The study also found positive correlations between MOTS-c levels and VO2 max, grip strength, and skeletal muscle index on DEXA, consistent with the hypothesis that MOTS-c is a functional biomarker of mitochondrial health. Limitations included the cross-sectional design (preventing causal inference) and reliance on a single ELISA platform for MOTS-c quantification, which has known inter-assay variability issues at the low nanomolar concentrations present in human serum. ^[9]

Study 3: Reynolds et al. (2021), Nature Aging - Healthspan Extension in Aged Mice

The Reynolds et al. Nature Aging paper is among the most comprehensive in-vivo MOTS-c studies published to date, examining the effects of chronic MOTS-c administration on healthspan in aged mice (22 months, equivalent to approximately 65-70 human years). ^[7] The study used subcutaneous (SC) injection at 5 mg/kg three times per week in C57BL/6 mice over 12 weeks. Key endpoints included treadmill endurance, grip strength, rotarod performance, body composition by MRI, metabolic cage parameters (VO2, RER, locomotor activity), inflammatory cytokine panels, and muscle histology.

MOTS-c-treated aged mice showed significantly improved treadmill endurance (approximately 22% increase in time to exhaustion), maintained lean mass, reduced visceral adipose tissue, and improved insulin sensitivity compared to vehicle controls. Histological analysis of gastrocnemius muscle showed a shift toward increased type I (oxidative) fiber proportion and higher mitochondrial density by electron microscopy. Inflammatory cytokines (IL-6, TNF-alpha) were reduced in MOTS-c-treated animals' serum at study termination. The authors performed RNA-sequencing on skeletal muscle and liver, revealing upregulation of mitochondrial biogenesis gene sets (PPARGC1A, TFAM, NRF1) and downregulation of senescence-associated secretory phenotype (SASP) gene clusters in MOTS-c animals. This transcriptomic profile is particularly noteworthy for longevity researchers, as SASP suppression is a major mechanistic target in the senolytic/senostatic research space.

Limitations of the Reynolds study include the single-sex design (female mice only in the main cohort), the relatively small group sizes (n=8-10 per arm), and the lack of lifespan rather than healthspan as a primary endpoint. Whether the improvements in functional metrics translate to actual longevity rather than compressing morbidity requires dedicated survival studies, which have not yet been published for MOTS-c specifically. ^[7]

Study 4: Kim et al. (2018), Cell Metabolism - Nuclear Translocation Under Stress

The 2018 Kim et al. paper in Cell Metabolism expanded the mechanistic understanding of MOTS-c substantially by demonstrating nuclear translocation. ^[3] The experimental system used human osteosarcoma cells (143B) and primary human fibroblasts subjected to mitochondrial stressors (hydrogen peroxide, oligomycin, FCCP), with MOTS-c localization tracked by tagged protein constructs and immunofluorescence. The paper used CRISPR-based deletion of the MOTS-c sORF to generate null cells, providing cleaner genetic evidence than RNA interference approaches.

The core finding was that MOTS-c translocates to the nucleus within 30-60 minutes of mitochondrial stress initiation, where it binds to antioxidant response elements (ARE) and modulates the transcription of NRF2-target genes involved in reactive oxygen species (ROS) defense. This positions MOTS-c as a retrograde signal from the mitochondria to the nucleus, a member of what is sometimes called the "mitochondrial stress signaling" network. The functional consequence in cell culture was increased survival under oxidative stress conditions: MOTS-c null cells showed ~40% higher cell death under H2O2 treatment compared to wild-type controls, and this was rescued by exogenous MOTS-c addition at 1 micromolar concentration. The dose-response relationship in this cell-stress assay showed EC50 values in the 50-200 nM range, which is relevant to researchers designing in-vitro experiments and selecting appropriate stock concentrations. ^[3]

Study 5: Lu et al. (2019), Aging - Cognitive and Neuronal Effects

Lu et al. published a study in the journal Aging (2019) investigating MOTS-c effects in Alzheimer's disease model mice (5xFAD transgenic strain). ^[10] The literature-reported research dose used was 5 mg/kg IP, three times per week, over eight weeks. Treated animals showed reduced amyloid plaque burden (measured by thioflavin S staining and ELISA for Abeta42), improved performance on Morris water maze spatial memory test, and lower neuroinflammatory markers (Iba-1 positive microglia counts, cortical IL-1beta). Mechanistically, the authors proposed that AMPK activation in neural tissue reduced mTORC1 signaling, enhancing autophagy and thus amyloid clearance. The NF-kB suppression documented in peripheral macrophage studies appeared to extend to central microglia.

This study is methodologically weaker than the Reynolds or Lee primary papers: the 5xFAD model is known to be aggressively amyloidogenic and may not accurately model sporadic late-onset Alzheimer's disease, the behavioral testing was performed by investigators not blinded to treatment assignment (acknowledged limitation), and the n values were small (n=6 per group). These limitations mean the cognitive data should be interpreted as hypothesis-generating rather than confirmatory, but the mechanistic plausibility is supported by the convergence of AMPK and autophagy pathways with established Alzheimer's disease biology. ^[10]

Study 6: Ramanjaneya et al. (2019), Frontiers in Endocrinology - Human MOTS-c and Metabolic Syndrome

Ramanjaneya et al. conducted a cross-sectional clinical study measuring serum MOTS-c in 85 adults with varying degrees of metabolic syndrome compared to 40 healthy controls. ^[11] MOTS-c levels were significantly lower in subjects with metabolic syndrome (median 0.18 nM vs. 0.41 nM in controls, P<0.001), with the strongest inverse correlations with fasting insulin, HOMA-IR, and waist circumference. The relationship persisted after adjustment for age, sex, and BMI, suggesting that MOTS-c deficiency is independently associated with insulin resistance rather than being a secondary consequence of adiposity alone. This epidemiological data strengthens the mechanistic inference from rodent intervention studies but, as with all cross-sectional designs, cannot establish whether low MOTS-c causes metabolic syndrome, results from it, or is a parallel consequence of a third upstream factor (such as reduced mitochondrial mass or function). ^[11]

Pharmacokinetics

Pharmacokinetic data for MOTS-c in human subjects is minimal as of early 2026. The available information derives from rodent PK studies and limited human exercise physiology observations. The table below summarizes current literature-reported PK parameters.

The short plasma half-life of MOTS-c (estimated 30-45 minutes in rodent studies) has important implications for research protocol design. Daily IP injections, as used in the Lee 2015 study, or three-times-weekly SC injections, as in Reynolds 2021, produce intermittent rather than sustained elevations in circulating MOTS-c. Whether the biological effects observed reflect peak concentration, trough concentration, or area under the curve exposure has not been systematically characterized. This is a genuine gap in the pharmacological foundation of current MOTS-c research, and it complicates dose extrapolation across species. ^{[1] [7]}

The mechanism of cellular uptake of exogenous MOTS-c is not fully characterized. The peptide's positive charge facilitates interaction with negatively charged cell membrane phospholipids, and passive endocytic uptake has been proposed. Whether specific receptor-mediated internalization exists remains unknown. For nuclear translocation to occur, at least a fraction of internalized peptide must escape endosomal processing, which is common for basic-charge peptides but also implies variable efficiency depending on cell type and metabolic state. ^[3]

Purity and Verification

What a Compliant CoA Should Contain

A certificate of analysis for research-grade MOTS-c at the 30 mg scale should include, at minimum, the following components. First, an HPLC chromatogram with integration showing peak purity expressed as percentage area under the main peak, with all detectable impurities identified by retention time. For MOTS-c at ≥98% stated purity, the main peak should account for ≥98% of total UV area at 220 nm (peptide bond detection) or 280 nm (aromatic residue detection). A chromatogram without integration percentages or axis labels is non-informative and should be treated as a red flag. ^[12]

Second, the CoA should include mass spectrometry data confirming the molecular ion. For MOTS-c (MW 2174.77 Da), ESI-MS should show the expected multiply-charged ion series. The [M+2H]²⁺ species should appear at approximately 1088.4 m/z, the [M+3H]³⁺ at approximately 725.9 m/z. A CoA showing only a single mass or an incorrect molecular weight is a quality failure. MALDI-TOF is an acceptable alternative, but ESI-MS with isotope resolution provides better confidence at this molecular weight.

Third, the CoA should specify the moisture content of the lyophilized material, typically by Karl Fischer titration. Lyophilized peptides typically contain 5-12% residual water by weight; if the stated amount per vial is given as net peptide weight (dry weight corrected), this is preferable to total lyophilate weight. Some vendors list 30 mg total lyophilate, which may contain only 26-28 mg of actual peptide. Researchers calculating molar doses need to account for this.

Independent Verification Approaches

The gold standard for independent verification of research peptide identity and purity is liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). A 16-residue peptide like MOTS-c can be fully sequence-confirmed by CID fragmentation, which generates b-ion and y-ion series covering the entire sequence. Any core university mass spectrometry facility or contract analytical laboratory (e.g., Eurofins, Covance, SGS) can perform this analysis from a small aliquot (0.1-0.5 mg). The cost is typically $50-150 per sample, which is trivially small relative to the cost of an in-vivo study that might consume the entire 30 mg vial.

For routine purity confirmation without full sequencing, a laboratory with a reverse-phase HPLC instrument can run the received material against an in-house standard curve or simply compare the chromatographic profile to the vendor-provided CoA. Discrepancies in retention time of more than 0.5 minutes under the same gradient conditions are cause for concern. Researchers setting up a MOTS-c quality control program should consider running HPLC on a portion of each new vial before committing it to a longitudinal study. For guidance on certificate of analysis interpretation, see our guide to reading peptide CoAs.

Dosage and Reconstitution

Literature-Reported Research Doses

The most frequently cited in-vivo research doses for MOTS-c in murine models are:

• 15 mg/kg/day IP (Lee et al. 2015, C57BL/6, HFD model, metabolic endpoints) ^[1]
• 5 mg/kg three times per week SC (Reynolds et al. 2021, aged C57BL/6, healthspan endpoints) ^[7]
• 5 mg/kg three times per week IP (Lu et al. 2019, 5xFAD, cognitive endpoints) ^[10]
• 10 mg/kg/day IP (Zhu et al. 2021, STZ-diabetic model, insulin sensitivity endpoints) ^[13]

The variation in dose across studies reflects different research questions, delivery routes, and model systems. The higher 15 mg/kg IP dose was used in the initial acute metabolic study; subsequent chronic aging studies have typically used lower doses (5-10 mg/kg) to minimize non-specific stress from injection volume and to more closely model potential physiologically relevant exposures.

For in-vitro cell culture work, effective concentrations in the literature range from 0.1 to 10 micromolar, with most mechanistic studies using 1-5 micromolar as the primary experimental concentration. EC50 for AMPK phosphorylation in L6 myotubes has been estimated at approximately 0.5-1 micromolar in two independent studies. ^{[1] [3]}

Reconstitution Worked Examples

Reconstitution of lyophilized MOTS-c follows standard peptide preparation practice. See our complete peptide reconstitution guide for technique details. Three worked numerical examples are provided below for different study scales.

Example 1: In-Vitro Cell Culture Stock Solution

Target: 1 mM master stock in sterile water from a portion of the 30 mg vial.

MW of MOTS-c = 2174.77 g/mol. Molecular weight in mg/nmol = 2.17477 mg/nmol.

To make 1 mL of 1 mM solution: need 1 mmol/L x 0.001 L x 2174.77 g/mol = 0.002175 g = 2.175 mg peptide.

Action: weigh out 2.2 mg of MOTS-c lyophilized powder into a low-binding tube. Add 1.0 mL sterile water (or PBS pH 7.4). Vortex gently for 20 seconds. Sonicate in ice bath for 30 seconds if not fully dissolved. This produces approximately 1 mM stock. Filter-sterilize through a 0.22-micron cellulose acetate syringe filter before cell culture addition. Aliquot into 50-100 microliter volumes and store at -80°C to minimize freeze-thaw degradation.

Example 2: Murine In-Vivo Study at 5 mg/kg

Mouse body weight: average 25 g (0.025 kg). Target dose: 5 mg/kg.

Dose per mouse = 5 mg/kg x 0.025 kg = 0.125 mg per injection.

Injection volume limit (IP for mice): typically 200-400 microliters. Using 200 microliters as target volume:

Required concentration = 0.125 mg / 0.200 mL = 0.625 mg/mL.

For a cohort of 10 mice receiving three injections per week for 12 weeks (36 injections per mouse, 360 total injections):

Total MOTS-c required = 360 x 0.125 mg = 45 mg. This exceeds a single 30 mg vial; plan for two vials per cohort arm.

From one 30 mg vial to make working solution at 0.625 mg/mL: reconstitute with 30 mg / 0.625 mg/mL = 48 mL sterile vehicle. This volume requires preparation of multiple small aliquots (e.g., 1 mL each in cryotubes) stored at -80°C to avoid freeze-thaw degradation of the bulk.

Example 3: Murine In-Vivo Study at 15 mg/kg

Mouse body weight: average 30 g (0.030 kg, HFD model, heavier). Target dose: 15 mg/kg.

Dose per mouse = 15 mg/kg x 0.030 kg = 0.45 mg per injection.

For 200 microliter injection volume: required concentration = 0.45 mg / 0.200 mL = 2.25 mg/mL.

For a cohort of 10 mice receiving daily injections over 28 days (280 total injections):

Total MOTS-c required = 280 x 0.45 mg = 126 mg. This requires between four and five 30 mg vials for a single cohort arm, which underscores why the 30 mg format is the most practical starting point for this dose range even though larger multi-arm studies will require multiple vials.

For dosage calculation methodology and allometric scaling reference tables, see our dosage calculation guide.

Storage Recommendations for Reconstituted Material

Reconstituted MOTS-c solutions should be stored at -80°C for any storage exceeding 48 hours. At 4°C, reconstituted solutions are considered stable for no more than 5-7 days, with the primary degradation risk being methionine oxidation and non-specific adsorption to tube surfaces. Low-binding polypropylene tubes are recommended. Avoid repeated freeze-thaw cycles; aliquoting into single-use volumes before initial freezing is strongly recommended. The lyophilized powder remaining in sealed vials is stable at -20°C for 24 months or more under standard conditions, though vendors should specify their own stability data on the CoA.

Side Effects and Safety

Observed Adverse Effects in Animal Studies

Preclinical MOTS-c studies have generally reported a favorable tolerability profile in rodent models at the doses used. The Lee et al. (2015) study at 15 mg/kg/day IP over four weeks reported no overt signs of toxicity, no significant changes in liver enzyme panels (ALT, AST), creatinine, or complete blood count compared to vehicle controls. ^[1] The Reynolds et al. (2021) study at 5 mg/kg three times weekly over 12 weeks in aged mice similarly reported no injection-site pathology and no clinical signs of distress. ^[7]

One theoretical safety concern relates to the mechanism: MOTS-c's inhibition of the folate cycle could, at high doses, impair one-carbon metabolism and reduce available methyl groups for DNA methylation and nucleotide synthesis. In proliferating cells (including cancer cells), this could have anti-proliferative effects, which has led to some interest in MOTS-c as an oncology research tool, but also raises the theoretical concern that sustained folate pathway inhibition in normal rapidly-dividing tissues (gut epithelium, bone marrow) could produce adverse effects at high doses. No such effects have been reported in the published rodent studies, but the dose ranges explored in the literature are limited and long-term toxicology studies have not been published. ^[1]

Hypoglycemia represents a theoretically plausible concern given MOTS-c's insulin-sensitizing and AMPK-activating effects, particularly in combination with other hypoglycemic research compounds. Animal studies have not reported hypoglycemic events at study doses, but co-administration with insulin or other anti-hyperglycemic compounds would be expected to require careful blood glucose monitoring in in-vivo protocols. ^[2]

Immunogenicity Considerations

As a 16-residue peptide derived from a human endogenous sequence, MOTS-c has low predicted immunogenicity in humans (though this is irrelevant to the non-clinical research context). In rodent models, no anti-MOTS-c antibody formation has been reported in the peer-reviewed studies, though none of the published studies specifically tested for this. Researchers running long-term rodent studies (beyond 12 weeks) using exogenous MOTS-c should be aware of this gap in the literature and consider including an immunogenicity assay (ELISA for anti-MOTS-c IgG in terminal serum samples) as a secondary endpoint. ^[7]

Unknown Risks

The honest assessment is that formal preclinical toxicology for MOTS-c, including repeat-dose GLP toxicity studies, genotoxicity battery, and reproductive toxicology, has not been published. The published in-vivo data represents efficacy-focused studies in healthy or disease-model rodents, not safety-focused studies. The absence of reported adverse effects in these studies is reassuring but is not equivalent to a safety package. Researchers handling MOTS-c solutions should apply standard laboratory safety practices for handling peptide solutions of unknown systemic risk.

How It Compares

MOTS-c vs. Humanin: The Closest Comparator

Humanin and MOTS-c share the distinction of being the two best-characterized MDPs. Humanin was described earlier (2003, Hashimoto et al.) and binds to a defined heterotrimeric receptor complex including CNTFR, WSX-1, and gp130, giving it a more precisely characterized receptor-level pharmacology than MOTS-c. ^[14] Humanin's primary studied effects are in neuronal cell survival and IGF-1/IGF-1R modulation, with some overlap with insulin sensitivity. MOTS-c appears to have a broader tissue distribution and stronger skeletal muscle effects, making the two peptides complementary rather than redundant for research purposes. Some research groups have investigated them in combination, though published combination data remains sparse. Researchers interested in MDP biology should review both compounds; for MOTS-c specifically, the metabolic and exercise biology applications are better supported by current literature. ^[7]

MOTS-c vs. SS-31 (Elamipretide): Mitochondrial Mechanism Contrast

SS-31 is another mitochondrially-targeted research peptide with a distinct mechanism: it physically associates with cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and improving electron transport chain (ETC) efficiency. ^[15] While both MOTS-c and SS-31 ultimately improve mitochondrial function, their mechanisms are non-overlapping and they operate at different stages of the metabolic cascade. SS-31 works within the mitochondrial inner membrane; MOTS-c is translated there but acts primarily in the cytoplasm and nucleus after export. SS-31 has advanced to phase II clinical trials in Barth syndrome (a mitochondrial cardiomyopathy), giving it the strongest human translational data of any mitochondrially-targeted peptide currently in research. MOTS-c has no published human intervention data as of 2026. ^[15]

MOTS-c vs. Epitalon: Longevity Category Comparison

Epitalon (Epithalon) is a synthetic tetrapeptide analogue of Epithalamin, isolated from bovine pineal extract by Anisimov and Khavinson's group at the N.N. Petrov Institute in St. Petersburg. The claimed mechanism involves telomerase activation and normalization of hypothalamic-pituitary-gonadal axis function in aged animals. ^[16] The evidence base is predominantly from the originating group, with limited independent replication, which is a significant scientific limitation. MOTS-c has a stronger independent replication record: the core metabolic findings from Lee (2015) have been replicated by at least four independent groups in different institutions and countries. For researchers prioritizing reproducibility of the biological foundation, MOTS-c currently has an advantage. However, the peptide research community should apply consistent skepticism to both compounds given the absence of randomized controlled human data for either.

Where to Buy

Apollo Peptide Sciences is the affiliate vendor for this product. Their MOTS-c 30mg listing is available through our internal review page at /product/mots-c-30mg, which includes the current pricing, stock status, and links to their CoA downloads. We have reviewed their analytical documentation for this batch as part of our standard vendor evaluation process.

When evaluating any MOTS-c vendor, the following criteria are non-negotiable for research-quality material: HPLC purity ≥98% with downloadable chromatogram; ESI-MS or MALDI-TOF confirmation of correct MW; clear specification of whether vial weight is net peptide or total lyophilate; cold-chain shipping for orders in warm climates; and a clear lot number tied to the CoA. For a comparison of currently rated peptide suppliers across the MOTS-c category and other longevity compounds, see our suppliers directory.

The 30 mg vial at $150.00 works out to $5.00/mg. For comparison, 5 mg vials from other vendors typically range from $30-45 (equivalent to $6-9/mg), making the 30 mg format from Apollo meaningfully more cost-efficient for research groups planning multi-arm studies. The primary consideration against the 30 mg format is the stability risk: once the sealed vial is opened, the entire 30 mg must be handled carefully. Research groups running smaller pilot studies may prefer to start with a 5 mg or 10 mg vial for initial protocol development before committing to the bulk format. See our full MOTS-c 30mg product page for the current affiliate link and independent third-party review details.

Open Research Questions

Despite the relatively rapid development of the MOTS-c literature since 2015, several substantive scientific questions remain unresolved.

Receptor identification: Unlike humanin, MOTS-c does not have a confirmed plasma-membrane receptor. The mechanism by which extracellular MOTS-c enters cells, and whether a specific receptor mediates its uptake and downstream signaling initiation, is unknown. This gap limits the ability to design receptor-competitive pharmacological studies or to identify tissues most likely to respond to exogenous administration based on receptor expression mapping.

Human dose-response: No dose-escalation or pharmacodynamic study in humans has been published. All human-relevant inferences are based on allometric scaling from rodent data, which is known to be unreliable for peptides due to species differences in proteolytic clearance, receptor density, and tissue distribution. The human PK profile remains entirely uncharacterized.

Sex differences: Several published studies used single-sex cohorts (often female mice). Whether the metabolic and aging effects of MOTS-c differ between male and female animals, and by what mechanism, is largely uninvestigated. Given well-documented sex differences in metabolic responses to AMPK activation, this is an important gap.

Longevity vs. healthspan: The published studies have measured functional endpoints (exercise capacity, insulin sensitivity, muscle mass) rather than lifespan. Whether MOTS-c supplementation extends maximum lifespan in any model organism remains unpublished. The distinction between compressing morbidity (healthspan extension) and extending maximum lifespan is important for framing MOTS-c within the broader longevity science context.

Combination biology with other MDPs: Whether MOTS-c and humanin have additive, synergistic, or antagonistic effects when both are present at supraphysiological concentrations is unexplored. Given that both peptides are derived from mitochondrial DNA and presumably co-secreted under stress conditions, understanding their combined biology is relevant to any physiologically meaningful model of MDP function.

Cancer biology interactions: MOTS-c's antiproliferative effects on some cancer cell lines via folate pathway inhibition and AMPK activation raises the question of whether exogenous MOTS-c administration affects tumor growth or immune surveillance in cancer-bearing animals. No oncology model study has been published.

FAQ